Randomized Phase II Trial of Concurrent Chemoradiotherapy +/- Metformin HCL in Locally Advanced NSCLC
Principal Investigator
Theos Tsakiridis, MD
Status
Terminated
Date Opened To Accrual
August 25 2014
Date Closed to Accrual
December 15 2016
Date of Study Termination
September 04 2025
Disease Site
Lung [LU]
Non-small Cell Lung Cancer
Phase
II
Developmental Therapeutics
No
Primary Objective
To determine whether MET added to chemoradiotherapy can improve progression-free survival (PFS) in patients with locally advanced NSCLC
Patient Population
Pathologically proven diagnosis of Stage IIIA or IIIB non-small cell lung cancer; patients must have unresectable disease, are medically inoperable, or are not willing to undergo surgical management.
Target Accrual
168
Patient Study Webpage
There is no available patient study webpage available for this trial at this time.